CN110913909A - 治疗肿瘤的方法 - Google Patents

治疗肿瘤的方法 Download PDF

Info

Publication number
CN110913909A
CN110913909A CN201880044783.XA CN201880044783A CN110913909A CN 110913909 A CN110913909 A CN 110913909A CN 201880044783 A CN201880044783 A CN 201880044783A CN 110913909 A CN110913909 A CN 110913909A
Authority
CN
China
Prior art keywords
cells
nanoparticles
tumor
ionizing radiation
gdbn
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880044783.XA
Other languages
English (en)
Chinese (zh)
Inventor
F·卢克斯
O·蒂耶芒
J-L·佩尔弗蒂尼
E·德奇
F·劳
A·阿卢奇
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nh Agix Treatment
Centre National de la Recherche Scientifique CNRS
Institut Gustave Roussy (IGR)
Institut National de la Sante et de la Recherche Medicale INSERM
Universite Claude Bernard Lyon 1
Original Assignee
Nh Agix Treatment
Centre National de la Recherche Scientifique CNRS
Institut Gustave Roussy (IGR)
Institut National de la Sante et de la Recherche Medicale INSERM
Universite Claude Bernard Lyon 1
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nh Agix Treatment, Centre National de la Recherche Scientifique CNRS, Institut Gustave Roussy (IGR), Institut National de la Sante et de la Recherche Medicale INSERM, Universite Claude Bernard Lyon 1 filed Critical Nh Agix Treatment
Publication of CN110913909A publication Critical patent/CN110913909A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/242—Gold; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/244—Lanthanides; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/547—Chelates, e.g. Gd-DOTA or Zinc-amino acid chelates; Chelate-forming compounds, e.g. DOTA or ethylenediamine being covalently linked or complexed to the pharmacologically- or therapeutically-active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A61K47/6933—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained by reactions only involving carbon to carbon, e.g. poly(meth)acrylate, polystyrene, polyvinylpyrrolidone or polyvinylalcohol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N2005/1092—Details
    • A61N2005/1098—Enhancing the effect of the particle by an injected agent or implanted device

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pathology (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CN201880044783.XA 2017-07-05 2018-07-04 治疗肿瘤的方法 Pending CN110913909A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17305869.4 2017-07-05
EP17305869.4A EP3424533A1 (en) 2017-07-05 2017-07-05 Methods for treating tumors
PCT/EP2018/068099 WO2019008040A1 (en) 2017-07-05 2018-07-04 METHODS OF TREATING TUMORS

Publications (1)

Publication Number Publication Date
CN110913909A true CN110913909A (zh) 2020-03-24

Family

ID=59363059

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880044783.XA Pending CN110913909A (zh) 2017-07-05 2018-07-04 治疗肿瘤的方法

Country Status (9)

Country Link
US (1) US20210128730A1 (enExample)
EP (2) EP3424533A1 (enExample)
JP (1) JP7386711B2 (enExample)
KR (1) KR102799910B1 (enExample)
CN (1) CN110913909A (enExample)
AU (1) AU2018296426B2 (enExample)
CA (1) CA3068355A1 (enExample)
TW (1) TWI796340B (enExample)
WO (1) WO2019008040A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116782953A (zh) * 2020-11-19 2023-09-19 Nh阿吉克斯治疗公司 用于通过捕获铜和/或铁治疗肿瘤的方法

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2959502B1 (fr) 2010-04-30 2012-09-07 Nanoh Nanoparticules ultrafines a matrice polyorganosiloxane fonctionnalisee et incluant des complexes metalliques ; leur procede d'obtention et leurs applications en imagerie medicale et/ou therapie
CA3148734A1 (en) 2019-07-29 2021-02-04 Nh Theraguix High-z-element containing nanoparticles for use in the treatement of tumors
FR3099883A1 (fr) 2019-08-14 2021-02-19 Nh Theraguix Nanoparticules pour le traitement du cancer par rayonnement de radiofréquence
TWI833803B (zh) * 2019-09-12 2024-03-01 法商Ｎｈ蕾哈吉公司 含有高ｚ元素之奈米顆粒在製備用於治療腫瘤之藥物之用途
EP3795178A1 (en) 2019-09-19 2021-03-24 Nh Theraguix Methods for triggering m1 macrophage polarization
EP4096781A1 (en) 2020-01-28 2022-12-07 RefleXion Medical, Inc. Joint optimization of radionuclide and external beam radiotherapy
AU2021270780A1 (en) 2020-05-15 2022-11-24 Centre Georges-François Leclerc Methods for image-guided radiotherapy
CA3084780A1 (en) * 2020-06-24 2021-12-24 Rodney HERRING Use of low iron oxide iron-doped titanium dioxide nanoparticles in the treatment of tumors and other diseases
FR3116216B1 (fr) 2020-11-19 2023-10-27 Nh Theraguix Procédé de préparation de nanoparticules
CN120359049A (zh) 2022-07-13 2025-07-22 蒙彼利埃大学 纳米颗粒和放射性药物的联合疗法
WO2024058504A1 (ko) * 2022-09-16 2024-03-21 (주)한국원자력 엔지니어링 앱스코팔 효과를 갖는, 암의 예방 또는 치료용 조성물 및 이를 이용한 암의 예방 또는 치료방법
EP4605019A2 (en) 2022-10-18 2025-08-27 Nh Theraguix Methods for imaging using spcct
WO2024236048A1 (en) 2023-05-16 2024-11-21 Nh Theraguix Combination therapy for treating tumors with radiotherapy
FR3151755A1 (fr) 2023-07-31 2025-02-07 Nh Theraguix Procédé de quantification de la concentration d’un agent de contraste et dispositif associé

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011135101A2 (fr) * 2010-04-30 2011-11-03 Nanoh Nanoparticules ultrafines a matrice polyorganosiloxane fonctionnalisee et incluant des complexes metalliques; leur procede d'obtention et leurs applications en imagerie medicale et/ou therapie
US20110269808A1 (en) * 2007-03-14 2011-11-03 Astex Therapeutics Limited Compositions comprising (s)-2-amino-1-(4-chlorophenyl)-1-[4-(1h-pyrazol-4-yl)-phenyl]-ethanol as modulator of protein kinases
CN104684546A (zh) * 2012-06-07 2015-06-03 哈佛大学校长及研究员协会 用于药物靶向的纳米疗法
US20150374818A1 (en) * 2013-01-25 2015-12-31 Nanobiotix Inorganic nanoparticles compositions in combination with ionizing radiations for treating cancer
US20160354333A1 (en) * 2015-06-03 2016-12-08 UND Life Sciences, LLC Compositions of polyunsaturated fatty acids and methods of use thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004509967A (ja) 2000-09-25 2004-04-02 ザ、プロクター、エンド、ギャンブル、カンパニー 医学及び治療法の適用に使用するための金属錯体
FR2867180B1 (fr) 2004-03-02 2006-06-16 Univ Claude Bernard Lyon Nanoparticules hybrides comprenant un coeur de ln203 porteuses de ligands biologiques et leur procede de preparation
US20060084666A1 (en) * 2004-10-18 2006-04-20 Harari Paul M Combined treatment with radiation and an epidermal growth factor receptor kinase inhibitor
FR2922106B1 (fr) 2007-10-16 2011-07-01 Univ Claude Bernard Lyon Utilisation de nanoparticules a base de lanthanides comme agents radiosensibilisants.
DK2867368T3 (da) * 2012-07-06 2022-01-31 Roussy Inst Gustave Samtidig detektering af kannibalisme og senescens som prognostisk markør for cancer
KR101662755B1 (ko) * 2015-04-28 2016-10-05 한국생명공학연구원 Nox5의 발현 또는 활성을 억제하는 제제를 포함하는 암 치료용 조성물
US11096962B2 (en) * 2015-05-28 2021-08-24 Nanobiotix Nanoparticles for use as a therapeutic vaccine

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110269808A1 (en) * 2007-03-14 2011-11-03 Astex Therapeutics Limited Compositions comprising (s)-2-amino-1-(4-chlorophenyl)-1-[4-(1h-pyrazol-4-yl)-phenyl]-ethanol as modulator of protein kinases
WO2011135101A2 (fr) * 2010-04-30 2011-11-03 Nanoh Nanoparticules ultrafines a matrice polyorganosiloxane fonctionnalisee et incluant des complexes metalliques; leur procede d'obtention et leurs applications en imagerie medicale et/ou therapie
CN104684546A (zh) * 2012-06-07 2015-06-03 哈佛大学校长及研究员协会 用于药物靶向的纳米疗法
US20150374818A1 (en) * 2013-01-25 2015-12-31 Nanobiotix Inorganic nanoparticles compositions in combination with ionizing radiations for treating cancer
US20160354333A1 (en) * 2015-06-03 2016-12-08 UND Life Sciences, LLC Compositions of polyunsaturated fatty acids and methods of use thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
FLORENCE TAUPIN ET AL: "Gadolinium nanoparticles and contrast agent as radiation sensitizers", 《PHYS. MED. BIOL.》 *
LENKA ŠTEFANČÍKOVÁ ET AL: "Cell localisation of gadolinium-based nanoparticles and related radiosensitising efficacy in glioblastoma cells", 《CANCER NANOTECHNOLOGY》 *
韩晓燕 等: "NOX家族蛋白的研究进展", 《生命科学》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116782953A (zh) * 2020-11-19 2023-09-19 Nh阿吉克斯治疗公司 用于通过捕获铜和/或铁治疗肿瘤的方法

Also Published As

Publication number Publication date
KR20200026290A (ko) 2020-03-10
TW201906636A (zh) 2019-02-16
EP3648793A1 (en) 2020-05-13
AU2018296426B2 (en) 2024-04-04
KR102799910B1 (ko) 2025-04-25
JP7386711B2 (ja) 2023-11-27
TWI796340B (zh) 2023-03-21
CA3068355A1 (en) 2019-01-10
WO2019008040A1 (en) 2019-01-10
AU2018296426A1 (en) 2020-01-16
US20210128730A1 (en) 2021-05-06
JP2020525467A (ja) 2020-08-27
EP3424533A1 (en) 2019-01-09

Similar Documents

Publication Publication Date Title
JP7386711B2 (ja) 腫瘍を治療するための方法
Zhu et al. Specific anti‐glioma targeted‐delivery strategy of engineered small extracellular vesicles dual‐functionalised by Angiopep‐2 and TAT peptides
Du et al. Designer exosomes for targeted and efficient ferroptosis induction in cancer via chemo-photodynamic therapy
Zheng et al. Metal nanoparticles as novel agents for lung cancer diagnosis and therapy
Jung et al. Overcoming the limits of hypoxia in photodynamic therapy: a carbonic anhydrase IX-targeted approach
CN102056628B (zh) 无机纳粒、其制备及用途
CN111840513A (zh) 一种负载促肿瘤凋亡蛋白和抗癌小分子的复合外泌体及其制备方法和应用
KR20120088665A (ko) 세포독성 화학요법제와 조합한 엔도텔린 수용체의 억제제를 이용한 뇌 전이 치료
US9295640B2 (en) Pharmaceutical composition for treating cancer using carbonate apatite nanoparticles
WO2011053901A2 (en) Magnetic nanostructures as theranostic agents
Wang et al. Emerging extracellular vesicle-based carriers for glioblastoma diagnosis and therapy
JP6612842B2 (ja) がんの脳転移の診断、予防及び治療方法、並びに血液脳関門を通過させるための医薬送達システム
Wang et al. Polyethylenimine mediated magnetic nanoparticles for combined intracellular imaging, siRNA delivery and anti-tumor therapy
JP7431940B2 (ja) 腫瘍を治療するための方法
Tripathi et al. Biological Cargo: Exosomes and their Role in Cancer Progression and Metastasis
US20230218781A1 (en) Methods for triggering m1 macrophage polarization
WO2021239730A1 (en) Nanoparticles, ionizing radiation and innovative therapeutic combinations thereof
Yang et al. Combination of porous Se@ SiO2 nanospheres and docetaxel exhibits anti-castration-resistant prostate cancer activity by downregulating ATG14-dependent autophagy
JP2023529660A (ja) エクストラドメイン－ｂフィブロネクチン標的プローブを用いた診断及びモニタリング
Song et al. Gadolinium-Based Nanoparticles Combined With Checkpoint Blockade Amplify Radiation-Induced Abscopal Effect And Cancer Immunotherapy
Sitia et al. HER-2-Targeted Nanoparticles for Breast Cancer Diagnosis and Treatment. Cancers 2022, 14, 2424
WO2024236048A1 (en) Combination therapy for treating tumors with radiotherapy
Kader Cellular and subcellular characterization of prostate carcinomas by molecular magnetic resonance imaging
WO2015121295A1 (en) Method for determining the level of hypoxia in a tumor
Yang Early Detection of Breast Cancer Using Molecular Beacons

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20200324